MART-1(27-35)

MART-1(27-35) is a synthetic peptide fragment derived from the melanoma antigen recognized by T cells 1 (MART-1), also known as Melan-A. As a nonapeptide corresponding to residues 27 through 35 of the MART-1 protein, it is widely recognized for its critical role in antigen presentation and T cell recognition within melanoma research. This peptide is a valuable tool for immunological studies focused on tumor-associated antigen processing, epitope mapping, and the characterization of cellular immune responses. Its well-defined sequence and immunogenic properties make it an essential reagent for investigating T cell specificity and the molecular mechanisms underlying tumor immunosurveillance.

Epitope Mapping: MART-1(27-35) is extensively utilized in epitope mapping studies to define the precise antigenic determinants recognized by cytotoxic T lymphocytes (CTLs). By incorporating this peptide into assays such as ELISPOT or peptide-MHC multimer staining, researchers can accurately identify and characterize T cell populations that are specific for the MART-1 antigen. This application is fundamental for dissecting the immunodominant regions of the MART-1 protein and understanding the fine specificity of T cell responses against melanoma-associated antigens.

Antigen Presentation Research: In the context of antigen processing and presentation, the MART-1(27-35) peptide serves as a model substrate for investigating how peptides are loaded onto major histocompatibility complex (MHC) class I molecules. Its defined sequence allows for controlled studies of peptide-MHC binding kinetics, stability, and the influence of various antigen-presenting cell types. These investigations are crucial for elucidating the molecular interactions that govern immune recognition and for optimizing protocols in immunological assays involving antigen-presenting cells.

T Cell Activation Assays: The peptide is frequently employed in functional assays to stimulate and assess antigen-specific T cell activation. By pulsing antigen-presenting cells with MART-1(27-35), researchers can evaluate T cell responses through cytokine release, proliferation, or cytotoxicity measurements. This approach is instrumental in monitoring immune competence, validating T cell receptor (TCR) specificity, and screening for effector functions in both basic research and preclinical settings.

Vaccine Development Research: MART-1(27-35) plays a significant role in the preclinical evaluation of peptide-based vaccine candidates targeting melanoma. Its immunogenic properties make it an ideal component for studying the induction of specific CTL responses in vitro and in animal models. Investigations using this peptide help to optimize vaccine formulations, adjuvant combinations, and delivery strategies aimed at enhancing antigen-specific immunity against tumor cells.

Immunomonitoring: The nonapeptide is a standard reagent in immunomonitoring protocols designed to track MART-1-specific T cell populations in experimental systems. By providing a defined stimulus, it enables precise quantification and phenotypic analysis of antigen-specific T cells over time. This capability is essential for longitudinal studies of immune responses, evaluation of immunotherapeutic interventions, and the development of robust biomarkers for immune monitoring in translational research.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

3. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

4. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

5. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats